Abstract
Background
The objective of the current study was to evaluate the toxicities and treatment response of intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
Methods
Intraoperative HIPEC (cisplatin 75 mg/m2, 41.5°C, 90 min) was performed in 30 patients with residual tumor of <1 cm after cytoreductive surgery between January 2007 and February 2008. All the patients received adjuvant chemotherapy with combination platinum and taxane. Adverse events and responses to primary treatment were evaluated and scored as follows: grade I, observation; grade II, medical treatment; grade III, intervention; and grade IV, reoperation or admission to the intensive care unit.
Results
No deaths or grade IV morbidities were observed. One hundred seven adverse events were identified in 30 patients (grade I, 40; grade II, 46; grade III, 21). The most common adverse events affected the hematologic system (n = 26), followed by the gastrointestinal system (n = 23). Most adverse events were anemias requiring transfusion and nausea/vomiting requiring medication. Twenty-eight patients (93%) experienced complete remission, and two patients (7%) had progressive disease.
Conclusion
HIPEC after extensive cytoreductive surgery for ovarian cancer is a procedure with acceptable morbidity that patients can tolerate. More follow-up is needed to determine the effect of HIPEC on survival.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
National Cancer Institute. NCI clinical announcement: intraperitoneal chemotherapy for ovarian cancer. 2006. Available at: http://ctep.cancer.gov/highlights/docs/clin_annc_010506.pdf. Accessed January 15, 2009.
Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.
Park S. Postoperative adjuvant intraperitoneal chemotherapy in patients with advanced ovarian cancer. Cancer Res Treat. 2006;38:36s–7s.
Vergote I, Amant F, Leunen K, et al. Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view. Oncologist. 2008;13:410–4.
Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006;100:27–32.
Sugarbaker PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia. 2007;23:431–42.
Helm CW, Bristow RE, Kusamura S, Baratti D, Deraco M. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol. 2008;98:283–90.
Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.
Yan TD, Zappa L, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Perioperative outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy for non-appendiceal peritoneal carcinomatosis from a prospective database. J Surg Oncol. 2007;96:102–12.
Gonzalez-Bayon L, Gonzalez-Moreno S, Ortega-Perez G. Safety considerations for operating room personnel during hyperthermic intraoperative intraperitoneal chemotherapy perfusion. Eur J Surg Oncol. 2006;32:619–24.
Vergote I, Rustin GJ, Eisenhauer EA, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst. 2000;92:1534–5.
Eisenhauer EL, D’Angelica MI, Abu-Rustum NR, et al. Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer. Gynecol Oncol. 2006;103:871–7.
Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol. 2006;13:635–44.
Yan TD, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma—a prospective study of 70 consecutive cases. Ann Surg Oncol. 2007;14:515–25.
Capone A, Valle M, Proietti F, et al. Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis. J Surg Oncol. 2007;96:507–13.
Kim S, Kim Y, Kim J. New paradigm of intraperitoneal chemotherapy in ovarian carcinoma. Korean J Gynecol Oncol. 2006;17:1–14.
Acknowledgments
We thank the anesthesiologists and surgery nurses of The Center for Uterine Cancer for their help and patience in performing HIPEC. We thank Wha-Eun Lee the research nurse at the National Cancer Center in Korea, for gathering the data.
This work was supported by grants 0710200-2 and 0710210-2 from the National Cancer Center in Korea.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lim, M.C., Kang, S., Choi, J. et al. Hyperthermic Intraperitoneal Chemotherapy After Extensive Cytoreductive Surgery in Patients with Primary Advanced Epithelial Ovarian Cancer: Interim Analysis of a Phase II Study. Ann Surg Oncol 16, 993–1000 (2009). https://doi.org/10.1245/s10434-008-0299-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-008-0299-y